Oregovomab

Oregovomab is a monoclonal antibody developed by CanariaBio. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: 2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04498117 (Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery), in ovarian cancer. The largest, NCT04498117, plans to enrol 615 participants (actual) with primary completion expected 2026-12-26. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.